Journavx to Treat Pain After Thumb Basal Joint Arthroplasty

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Rothman Institute Orthopaedics
Study ID
NCT07723352
Status
Enrolling By Invitation

Conditions

  • Joint Replacement
  • Joint Replacement Surgery
  • Postoperative Pain
  • Thumb Basal Joint Osteoarthritis

Eligibility Criteria

Sex
ALL
Age
40 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

  • suzetrigine 100mg — DRUG
    Participants will receive the recommended dosing for suzetrigine, which consists of a 100 mg oral loading dose taken in the recovery room prior to discharge, followed by 50 mg doses taken orally every 12 hours for 5 days, totaling 11 doses.
  • Acetaminophen — DRUG
    As part of the multimodal pain regimen, participants will also receive acetaminophen (Tylenol) (500 mg, every 4 hours, or 1000 mg, every 8 hours)

Study Details

The purpose of this study is to find out how well suzetrigine, a newly FDA-approved non-opioid pain medication, works to relieve pain after thumb basal joint replacement surgery. The researchers believe that suzetrigine may provide effective pain relief during recovery without the use of opioid medications.

Key Dates

First listed
Jul 23, 2026
Start date
Jul 21, 2026
Status verified
Jul 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Participants undergoing thumb Basal Joint Replacement Surgery
    Participants undergoing thumb Basal Joint Replacement Surgery receive suzetrigine (100 mg loading dose followed by 50 mg every 12 hours for 5 days) in combination with acetaminophen (Tylenol).

Primary Outcome Measure

Postoperative pain [ Time Frame: 5 days ]

Locations (1)

FacilityCityStateZIPSite coordinators
Rothman Orthopaedic InstitutePhiladelphiaPennsylvania19107-

Find similar trials in Philadelphia, PA

By research site
Rothman Orthopaedic Institute· Philadelphia, PA

Related Studies